Drug General Information (ID: DDIB5RSMH3)
Drug Name			Doxorubicin (liposomal)		Drug Info		Mercaptopurine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Antineoplastics
Structure

Mechanism of Doxorubicin (liposomal)-Mercaptopurine Interaction (Severity Level: Moderate)
Increased risk of hepatotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Doxorubicin (liposomal)				Mercaptopurine
Mechanism		Hepatotoxicity				Hepatotoxicity
Key Mechanism Factor 1
		Factor Name		Hepatotoxicity
		Factor Description		Combination of drugs that can induce hepatotoxicity may increase the risk of liver injury. Symptoms vary depending on the level of exposure and the total extent of liver damage, and may cause few symptoms if the damage is mild, and eventually lead to liver failure in patients with severe damage.
Mechanism Description		Increased risk of hepatotoxicity by the combination of Doxorubicin (liposomal) and Mercaptopurine

Recommended Action
Management		If concomitant therapy is needed, it is recommended to monitor patients for clinical and laboratory signs and symptoms of hepatotoxicity.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Purinethol (mercaptopurine). Glaxo Wellcome, Research Triangle Pk, NC.